HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David J Zammit Selected Research

PF-06263507

1/2021ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David J Zammit Research Topics

Disease

1Neoplasms (Cancer)
01/2021
1Inflammation (Inflammations)
10/2019
1Atopic Dermatitis (Atopic Eczema)
10/2019
1Pruritus (Itching)
10/2019
1Listeriosis (Listeria Infection)
02/2007
1Endotoxemia
02/2007
1Vesicular Stomatitis
08/2006
1Infections
04/2006

Drug/Important Bio-Agent (IBA)

3AntigensIBA
01/2021 - 04/2006
1PF-06263507IBA
01/2021
1Glycoproteins (Glycoprotein)IBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2021
1Ado-Trastuzumab EmtansineIBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1gusacitinibIBA
10/2019
1Biomarkers (Surrogate Marker)IBA
10/2019
1Janus KinasesIBA
10/2019
1CytokinesIBA
02/2007
1Viral AntigensIBA
04/2006